OBJECTIVE： To observe clinical efficacy and safety of Shuxuening injection in the adjunctive treatment of traumatic subarachnoid hemorrhage. METHODS： 96 patients with traumatic subarachnoid hemorrhage were randomly divided into control group and observation group with 48 patients in each group. Control group was given Tranexamic acid injection， Nimodipine injection and Citicoline injection， daily lumbar punctrive and determined intracranial pressure and drained cerebrospinal fluid via lumbar puncture； observation group was additionally given Shuxuening injection 20 ml added into 5％ Glucose injection 250 ml， ivgtt， qd. Both group were treated for consecutive 2 weeks. Clinical efficacy of 2 groups were observed， and GCS and MCA were also observed before and after treatment； ADR of 2 groups were recorded. RESULTS： Excellent rate of observation group （60.42％） was significantly higher than that of control group （31.25％）， with statistical significance （P＜0.05）. Before treatment， 3 and 5 days after treatment， there was no statistical significance in GCS and MCA between 2 groups （P＞0.05）； 7 and 14 days after treatment， GCS of 2 groups increased significantly while MCA decreased significantly， and the observation group was better than the control group， with statistical significance （P＜0.05）. The incidence of cerebral vasospasm， cerebral infarction and cerebral hemorrhage were 8.33％， 4.17％ and 4.17％ in observation group， and those of control group were 16.67％， 12.50％ and 16.67％； the observation group was significantly lower than the control group， with statistical significance （P＜0.05）. CONCLUSIONS： Shuxuening injection shows significant therapeutic efficacy in the adjunctive treatment of traumatic subarachnoid hemorrhage， with low incidence of ADR.